Shanghai Apeiron Biotechnology

Shanghai Apeiron Biotechnology is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies and treatments for respiratory diseases. The company's primary focus is on targeting the E3 ubiquitin ligase CBL-B, a key negative regulator of T cell and NK cell activation, to enhance the body's immune response against tumors. Their lead candidate, APN401, is a first-in-class autologous cell therapy that uses siRNA to silence CBL-B in peripheral blood mononuclear cells. Beyond oncology, the company has also explored recombinant human ACE2 for the treatment of acute respiratory distress syndrome and COVID-19. Apeiron maintains a global presence with operations in Shanghai and collaborations extending to Europe.